New drug combo shows promise for rare ovarian cancer
NCT ID NCT03531645
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot phase II study tests whether the drugs fulvestrant and abemaciclib can help control low-grade serous ovarian cancer in women with advanced disease. Up to 18 participants will receive the drugs before and after surgery. The goal is to see how many patients achieve a partial response, complete response, or stable disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fulvestrant (Faslodex) and abemaciclib
What this could lead to
If it works, this could offer a new treatment option to control low-grade serous ovarian cancer before and after surgery.
What could go wrong
This is a very small pilot study with only 18 participants, so results may not apply to all patients. The drugs are already approved for other cancers but are experimental for this type of ovarian cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States